Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243–262

Article  CAS  PubMed  Google Scholar 

Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R et al (2018) Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials. J Clin Oncol 36(6):572–580

Article  CAS  PubMed  Google Scholar 

Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B et al (2018) Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Ann Oncol 29(11):2200–2207

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lara PN Jr, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E et al (2014) Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst 106(4):dju013

Article  PubMed  PubMed Central  Google Scholar 

Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K et al (2016) Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 34(14):1652–1659

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC et al (2016) Predictors of time to metastasis in castration-resistant prostate cancer. Urology 96:171–176

Article  PubMed  Google Scholar 

Ando K, Sakamoto S, Saito S, Maimaiti M, Imamura Y, Sazuka T et al (2021) Prognostic value of high-sensitivity modified Glasgow prognostic score in castration-resistant prostate cancer patients who received docetaxel. Cancers (Basel) 13(4):773

Article  CAS  PubMed  Google Scholar 

Neuberger M, Goly N, Skladny J, Milczynski V, Weiß C, Wessels F et al (2022) Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort. J Cancer Res Clin Oncol 149(7):3371–3381

Article  PubMed  PubMed Central  Google Scholar 

Neuberger M, Skladny J, Goly N, Wessels F, Weiß C, Egen L et al (2022) Baseline modified Glasgow prognostic score [mGPS] predicts radiologic response and overall survival in metastatic hormone-sensitive prostate cancer treated with docetaxel chemotherapy. Anticancer Res 42(4):1911–1918

Article  CAS  PubMed  Google Scholar 

Yazgan SC, Yekedüz E, Utkan G, Ürün Y (2022) Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors. Prostate 82(15):1456–1461

Article  CAS  PubMed  Google Scholar 

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

Article  CAS  PubMed  Google Scholar 

Arlen PM, Bianco F, Dahut WL, D’Amico A, Figg WD, Freedland SJ et al (2008) Prostate specific antigen working group guidelines on prostate-specific antigen doubling time. J Urol 179:2181–2185

Article  PubMed  PubMed Central  Google Scholar 

Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107(4):695–699

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawahara T, Kato M, Tabata K, Kojima I, Yamada H, Kamihira O et al (2020) A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment. BMC Cancer 20(1):919

Article  CAS  PubMed  PubMed Central  Google Scholar 

McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12(3):223–226

Article  PubMed  Google Scholar 

Gil M, Gomes A, Baptista M, Vale Martins R, Nunes V (2022) Inflammatory and nutritional biomarkers as predictors of non-resectability and early recurrence in pancreatic and periampullary cancer. Minerva Surg 77(2):130–138

Article  PubMed  Google Scholar 

Freitas C, Jacob M, Tavares N, Cruz-Martins N, Souto-Moura C, Araújo D et al (2021) Modified Glasgow prognostic score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents. Anticancer Drugs 32(5):567–574

Article  CAS  PubMed  Google Scholar 

Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS (2012) Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow inflammation outcome study. Prostate Cancer Prostatic Dis 15:195–201

Article  CAS  PubMed  Google Scholar 

Shafique K, Proctor MJ, McMillan DC, Leung H, Smith K, Sloan B, Morrison DS (2013) The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer 13:292

Article  PubMed  PubMed Central  Google Scholar 

Linton A, Pond G, Clarke S, Vardy J, Galsky M, Sonpavde G (2013) Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer 11:423–430

Article  PubMed  Google Scholar 

Stangl-Kremser J, Mari A, Suarez-Ibarrola R, D’Andrea D, Korn SM, Pones M et al (2020) Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. Urol Oncol 38:600.e9-600.e15

Article  CAS  PubMed  Google Scholar 

Zhou Y, Lin C, Hu Z, Yang C, Zhang R, Ding Y et al (2021) Differences in survival of prostate cancer Gleason 8–10 disease and the establishment of a new Gleason survival grading system. Cancer Med 10(1):87–97

Article  CAS  PubMed  Google Scholar 

Gordetsky J, Epstein J (2016) Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol 11:25

Article  PubMed  PubMed Central  Google Scholar 

Chen WJ, Kong DM, Li L (2021) Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: a systematic review. Asian J Androl 23(2):163–169

Article  PubMed  Google Scholar 

Nishimoto M, Fujita K, Yamamoto Y, Hashimoto M, Adomi S, Banno E et al (2022) Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer. Transl Cancer Res 11(8):2681–2687

Article  CAS  PubMed  PubMed Central  Google Scholar 

Howard LE, Moreira DM, De Hoedt A, Aronson WJ, Kane CJ, Amling CL et al (2017) Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int 120(5B):E80–E86

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsubara N, Chi KN, Özgüroğlu M, Rodriguez-Antolin A, Feyerabend S, Fein L, Alekseev BY et al (2020) Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. Eur Urol 77(4):494–500

Article  CAS  PubMed  Google Scholar 

Markowski MC, Chen Y, Feng Z, Cullen J, Trock BJ, Suzman D et al (2019) PSA doubling time and absolute PSA predict metastasis-free survival in men with biochemically recurrent prostate cancer after radical prostatectomy. Clin Genitourin Cancer 17(6):470-475.e1

Article  PubMed  PubMed Central  Google Scholar 

Klaassen Z, Howard L, Wallis CJD, Janes JL, De Hoedt A, Aronson WJ et al (2022) Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time[< 9 months]? Prostate Cancer Prostatic Dis 26(1):151–155

Article  PubMed  Google Scholar 

Cui PF, Cong XF, Gao F, Yin JX, Niu ZR, Zhao SC, Liu ZL (2020) Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: a study of 1358 patients. World J Clin Cases 8(1):54–67

Article  PubMed  PubMed Central  Google Scholar 

Satapathy S, Mittal BR, Sood A (2020) Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate cancer treated with 177Lu-labeled prostate-specific membrane antigen radioligand therapy: a systematic review and meta-analysis. Clin Nucl Med 45(12):935–942

Article  PubMed  Google Scholar 

Shameem R, Hamid MS, Xu KY, Wu S (2015) Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer. World J Clin Oncol 6(4):64–72

Article  PubMed  PubMed Central  Google Scholar 

Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN et al (2015) Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis 18(2):122–127

Article  CAS  PubMed  PubMed Central  Google Scholar